Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: stable amino acid infusion Clear all
Completed Phase 2 Interventional Results available

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

NCT00402168
View directory record Official record
Conditions
Renal Transplant
Interventions
Belatacept, Cyclosporine A, Tacrolimus
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

NCT03976362
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 1, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional

High Dose IL 2 and Entinostat in RCC

NCT03501381
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Entinostat, Interleukin-2
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 1, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

NCT07527858
View directory record Official record
Conditions
Advanced Microsatellite Stable Colorectal Cancer
Interventions
Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
North Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Assessment of Cellular Metabolism in Humans

NCT02748369
View directory record Official record
Conditions
Normal Cellular Metabolism
Interventions
Somatostatin, Glucagon
Drug
Lead sponsor
K. Sreekumaran Nair
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 1, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

NCT05144009
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab Tesirine, Rituximab
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
65 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 1, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

NCT03511222
View directory record Official record
Conditions
Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Vorolanib, Nivolumab, Pembrolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT00027703
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 1, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

NCT01767792
View directory record Official record
Conditions
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions
Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

NCT01858922
View directory record Official record
Conditions
Hodgkin Disease
Interventions
ABVE-PC, DECA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 1, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322
View directory record Official record
Conditions
Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Interventions
Bevacizumab, FOLFIRI, Pelareorep
Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Homewood, Alabama • Beverly Hills, California • Encino, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373
View directory record Official record
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 1, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab+Ipilimumab+RT in MSS mCRC

NCT04575922
View directory record Official record
Conditions
Metastatic Microsatellite Stable Colorectal Cancer
Interventions
Nivolumab, Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Sep 1, 2026, 2:42 PM EDT
Not yet recruiting Phase 2 Interventional

Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors

NCT07647068
View directory record Official record
Conditions
Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor, Unresectable Malignant Gastrointestinal Stromal Tumor
Interventions
Aldesleukin, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography Test, Filgrastim, Fludarabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Surgical Procedure, Tumor Infiltrating Lymphocyte Therapy
Biological · Procedure · Drug
Lead sponsor
Joal Beane
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 1, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 1, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 1, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT04938232
View directory record Official record
Conditions
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 1, 2026, 2:42 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

NCT04141644
View directory record Official record
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
Ipilimumab, Osimertinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 1, 2026, 2:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Method To Measure Protein Digestion & Absorption

NCT02065141
View directory record Official record
Conditions
Chronic Heart Failure, Pulmonary Disorder, Chronic Obstructive
Interventions
sip feeding with stable isotope infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 1, 2026, 2:42 PM EDT
Terminated Phase 4 Interventional Results available

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

NCT01531803
View directory record Official record
Conditions
Hypovolemia
Interventions
Kedbumin 25%, Normal Saline Solution
Drug
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
Up to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Louisville, Kentucky • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 1, 2026, 2:42 PM EDT